Trius Therapeutics, Inc.  

(Public, NASDAQ:TSRX)   Watch this stock  
Find more results for TSRX
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -1.60
Shares 48.27M
Beta     -
Inst. own 59%

Key stats and ratios

Q2 (Jun '13) 2012
Net profit margin -1524.56% -198.37%
Operating margin -1466.69% -210.53%
EBITD margin - -208.10%
Return on average assets -96.35% -75.21%
Return on average equity -124.37% -101.10%
Employees 90 -
CDP Score - -


c/o Cubist Pharmaceuticals Inc., 65 Hayden Avenue
United States - Map
+1-781-8608660 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for life threatening infections. The Company is developing torezolid phosphate, an intraveneous (IV) and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections (ABSSSI), and subsequently for other indications. In addition, the Company is developing antibiotics for gram-negative infections using its discovery platform under two contracts: one funded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) and the other funded by the Defense Threat Reduction Agency (DTRA), a part of the Department of Defense. In September 2013, Cubist Pharmaceuticals Inc announced that it has completed the acquisition of Trius Therapeutics Inc.